Ocrevus
Ocrevus ingredients
| Active ingredient | Strength |
|---|---|
| Ocrelizumab | 300 mg/10mL |
What Ocrevus is used for
The FDA lists the approved uses on the official label (below). In the EU, ocrelizumab is approved as Ocrevus for:
Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. Treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Ocrevus
- Generic name
- Ocrelizumab
- Made by
- Genentech, Inc.
- Forms
- Injection
- Given
- Intravenous
- Drug class
- CD20-directed Cytolytic Antibody
- FDA approval
- Biologic licence (BLA) BLA761053
- On the US market since
- 2017
Official information
- Ocrevus prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Ocrelizumab)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Ocrevus?
Ocrevus (Ocrelizumab) is a cancer medicine made by Genentech, Inc., approved by the US FDA.
What are the ingredients of Ocrevus?
Ocrevus contains Ocrelizumab (300 mg/10mL).
Is Ocrevus approved in Europe?
The same active substance is approved in the EU as Ocrevus.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA